-
公开(公告)号：US07041503B2
公开(公告)日：2006-05-09
申请号：US08431644
申请日：1995-05-02
申请人： Steven H. Nye , Michael J. Lenardo , Henry F. McFarland , Louis A. Matis , Eileen Elliott Mueller , John P. Mueller , Clara M. Pelfrey , Stephen P. Squinto , James A. Wilkins
发明人： Steven H. Nye , Michael J. Lenardo , Henry F. McFarland , Louis A. Matis , Eileen Elliott Mueller , John P. Mueller , Clara M. Pelfrey , Stephen P. Squinto , James A. Wilkins
CPC分类号： C07K14/4713 , A61K38/00 , Y10S435/975
摘要： Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.
摘要翻译： 为多发性硬化症的临床评估，诊断和治疗提供了组合和方法。 本发明的组合物是与人髓磷脂碱性蛋白质的21.5kDa胎儿同种型相关的分子，并且包括核酸和多肽。 本发明的核酸分子可用于有效生产经修饰和未经修饰的21.5kDa髓鞘碱性蛋白多肽，所述多肽可用于测定T细胞对髓鞘碱性蛋白表位的响应性。 本发明的多肽也可用作通过诱导T细胞应答（包括细胞凋亡）作为治疗多发性硬化症的手段而起作用的治疗剂。
-
公开(公告)号：US06355245B1
公开(公告)日：2002-03-12
申请号：US08487283
申请日：1995-06-07
申请人： Mark J. Evans , Louis A. Matis , Eileen Elliott Mueller , Steven H. Nye , Scott Rollins , Russell P. Rother , Jeremy P. Springhorn , Stephen P. Squinto , Thomas C. Thomas , James A. Wilkins
发明人： Mark J. Evans , Louis A. Matis , Eileen Elliott Mueller , Steven H. Nye , Scott Rollins , Russell P. Rother , Jeremy P. Springhorn , Stephen P. Squinto , Thomas C. Thomas , James A. Wilkins
IPC分类号： A61K39395
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
摘要翻译： 公开了使用抗C5抗体，例如单克隆抗体来治疗肾小球性肾炎（GN）。 已经发现以低剂量水平施用此类抗体显着降低与GN相关的肾小球炎症/扩大和其它病理状况。 还公开了抗C5抗体和抗-C5抗体编码核酸分子。 这些抗体可用于治疗GN和涉及补体系统的病理活化的其它炎性病症。
-
公开(公告)号：US5643770A
公开(公告)日：1997-07-01
申请号：US278630
申请日：1994-07-21
申请人： James M. Mason , Stephen P. Squinto
发明人： James M. Mason , Stephen P. Squinto
IPC分类号： A61K48/00 , C12N15/48 , C12N15/867 , C12N15/86 , C07K14/15
CPC分类号： C12N15/86 , C07K14/005 , A61K48/00 , C12N2740/13022 , C12N2740/13043
摘要： Modified retroviral vector particles and modified retroviral producer cells producing such particles are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The modifications involve genetic alterations to effect the expression by these cells and particles of complement inhibitor activity. The genetic alterations involve the introduction of nucleic acid expression constructs directing the expression of retroviral SU(gp70)/complement inhibitor chimeric proteins into cells from which the producer cells are derived.
摘要翻译： 提供了产生这种颗粒的修饰的逆转录病毒载体颗粒和修饰的逆转录病毒产生细胞，用于促进涉及在含补体的体液存在下用逆转录病毒载体颗粒转导靶细胞的基因治疗方法。 修饰涉及遗传改变以影响这些细胞和补体抑制剂活性颗粒的表达。 遗传改变涉及将逆转录病毒SU（gp70）/补体抑制剂嵌合蛋白的表达引入导入生产细胞的细胞中的核酸表达构建体。
-
公开(公告)号：US5562904A
公开(公告)日：1996-10-08
申请号：US278550
申请日：1994-07-21
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P43/00 , C07K16/18 , C12P21/08 , B61K39/395
摘要： Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids prevents the complement mediated inactivation of the retroviral vector particles, and provides a safety mechanism for such gene therapy procedures, as the action of soluble complement inhibitors is transient, and any retroviral vector particles present after the return of uninhibited complement activity will be inactivated. Preferred soluble complement inhibitors for use in the practice of the present invention include complement inhibitory anti-complement component mAbs (including complement inhibitory anti C5 antibodies).
摘要翻译： 提供了方法和组合物，用于促进涉及在含补体的体液存在下用逆转录病毒载体颗粒转导靶细胞的基因治疗方法。 向体液施用可溶性补体抑制剂分子可防止补体介导的逆转录病毒载体颗粒的失活，并为此类基因治疗程序提供安全机制，因为可溶性补体抑制剂的作用是暂时的，并且任何逆转录病毒载体颗粒存在于 不受限制的补体活动的返回将被灭活。 用于实施本发明的优选的可溶性补体抑制剂包括补体抑制性抗补体成分mAb（包括补体抑制性抗C5抗体）。
-
公开(公告)号：US06316206B1
公开(公告)日：2001-11-13
申请号：US09211590
申请日：1998-12-14
IPC分类号： G01N3353
CPC分类号： C07K14/705 , A61K38/00 , C07K14/70571 , C07K2319/00 , C12Q1/6883 , C12Q2600/158
摘要： The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.
摘要翻译： 本发明涉及睫状神经营养因子（CNTF）受体，并提供CNTF受体核酸和氨基酸序列。 它还涉及（i）用于检测CNTF活性的测定系统; （ii）研究CNTF生理作用的实验模型系统; （ii）用于鉴定CNTF相关神经病症的诊断技术; （iv）用于治疗CNTF相关神经和肌肉病症的治疗技术，以及（v）用于鉴定与CNTF和CNTFR同源的分子的方法。
-
公开(公告)号：US5849897A
公开(公告)日：1998-12-15
申请号：US445073
申请日：1995-05-19
IPC分类号： A61K38/00 , C07K14/705 , C12N15/12 , C12Q1/68
CPC分类号： C07K14/705 , C07K14/70571 , C12Q1/6883 , A61K38/00 , C07K2319/00 , C12Q2600/158
摘要： The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.
摘要翻译： 本发明涉及睫状神经营养因子（CNTF）受体，并提供CNTF受体核酸和氨基酸序列。 它还涉及（i）用于检测CNTF活性的测定系统; （ii）研究CNTF生理作用的实验模型系统; （ii）用于鉴定CNTF相关神经病症的诊断技术; （iv）用于治疗CNTF相关神经和肌肉病症的治疗技术，以及（v）用于鉴定与CNTF和CNTFR同源的分子的方法。
-
公开(公告)号：US5624837A
公开(公告)日：1997-04-29
申请号：US458084
申请日：1995-06-01
IPC分类号： A01K67/027 , A61K38/00 , A61K48/00 , A61P37/06 , C07H21/04 , C07K14/705 , C07K19/00 , C12N5/10 , C12N15/09 , C12P21/02 , C12R1/92 , C12N5/16 , C12N15/62 , C12N15/63
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00
摘要： Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino terminal to the second functional domain. In this way, the chimeric protein exhibits both C3 and C5b-9 inhibitory activity. The other orientation, i.e., the orientation in which the second amino acid sequence is amino terminal to the first amino acid sequence, only produces C3 inhibitory activity. Nucleic acid molecules encoding such proteins are also provided.
摘要翻译： 提供了嵌合补体抑制蛋白，其包括具有C3抑制活性的第一功能结构域（第一氨基酸序列）和具有C5b-9抑制活性的第二功能结构域（第二氨基酸序列）。 第一功能域是第二功能结构域的氨基末端。 以这种方式，嵌合蛋白质表现出C3和C5b-9抑制活性。 另一取向即第二氨基酸序列与第一氨基酸序列氨基末端的取向仅产生C3抑制活性。 还提供了编码这种蛋白质的核酸分子。
-
公开(公告)号：US20120225056A1
公开(公告)日：2012-09-06
申请号：US13128523
申请日：2009-11-10
IPC分类号： A61K39/395 , A61K35/407 , A61K35/23 , A61K35/34 , A61K35/42 , A61P13/12 , A61K35/44 , A61K35/28 , A61K35/12 , A61P7/02 , A61P9/14 , A61K35/00 , A61K35/36
CPC分类号： C07K16/18 , A61K9/0019 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/34
摘要： The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
摘要翻译： 本公开尤其涉及包含人补体抑制剂的组合物和组合物在治疗或预防补体相关疾病的方法中的用途。 在一些实施方案中，将抑制剂长期施用于患者。 在一些实施方案中，抑制剂以一定量和频率施用于患者以维持系统性补体抑制并防止突破。 在一些实施方案中，组合物含有结合人补体成分C5蛋白或蛋白质片段如C5a或C5b的抗体或其抗原结合片段。
-
公开(公告)号：US06338820B1
公开(公告)日：2002-01-15
申请号：US09134141
申请日：1998-08-14
IPC分类号： G01N3500
CPC分类号： G01N35/025 , B01J19/0046 , B01J2219/00317 , B01J2219/00367 , B01J2219/00536 , B01J2219/0054 , B01J2219/00547 , B01J2219/00596 , B01J2219/00605 , B01J2219/00612 , B01J2219/00621 , B01J2219/00637 , B01J2219/00659 , B01J2219/00689 , B01J2219/00704 , B01J2219/00722 , B01J2219/00725 , B01J2219/00729 , C40B40/06 , C40B40/10 , C40B60/14 , C40B70/00 , G01N21/07 , G01N35/00029 , G01N35/00069 , G01N35/0099 , G01N2035/00237 , G01N2035/1034 , G01N2035/1062 , Y10T436/11 , Y10T436/111666 , Y10T436/115831 , Y10T436/2575
摘要： An apparatus for performing a assays includes an axially rotatable substrate including a plurality of layers of a semiconductor material and numerous radially-arrayed reaction sites. The apparatus further includes a rotary stepper motor which rotates the substrate at an adjustable and substantially continuous speed and controls the rotation of the substrate by adjusting the speed and a direction of rotation. In addition, the apparatus includes a dual function head which has a fluid dispenser that has a fluid dispenser outlet and delivers a fluid to a reaction site and also has a readout device that has a sensor which receives an identifying signal from the reaction site on the substrate or scans the substrate to read identifying marks at the reaction site. Moreover, the apparatus may be aligned by a computer having a memory for storing a start location for the dispenser outlet on the substrate and additional electronics. The computer provides movement signals to the rotary stepper motor and a linear stepper motor on which the dispenser outlet is mounted, whereby the motors align the dual function head over the substrate, such that the dispenser outlet is aligned over the reaction site.
摘要翻译： 用于进行测定的装置包括可轴向旋转的基底，其包括多个半导体材料层和许多径向排列的反应位点。 该装置还包括旋转步进电机，其以可调节且基本连续的速度旋转衬底，并通过调节速度和旋转方向来控制衬底的旋转。 此外，该装置包括双功能头，其具有流体分配器，该流体分配器具有流体分配器出口并将流体输送到反应部位，并且还具有读出装置，该读出装置具有接收来自反应部位的识别信号的传感器 底物或扫描底物以读取反应位点处的识别标记。 此外，该装置可以由具有用于存储基板上的分配器出口的起始位置和附加电子装置的存储器的计算机对准。 计算机向旋转步进电机和安装分配器出口的线性步进电机提供运动信号，由此电动机将双功能头对准衬底，使得分配器出口在反应部位上对准。
-
10.发明授权Use of C5-specific antibodies for reducing immune and hemostatic dysfunctions during extracorporeal circulation 失效在体外循环中使用C5特异性抗体降低免疫和止血功能障碍
公开(公告)号：US5853722A
公开(公告)日：1998-12-29
申请号：US575057
申请日：1995-12-21
IPC分类号： A61M1/36 , C07K16/18 , A61K39/395 , C07K16/36
CPC分类号： A61M1/3687 , C07K16/18
摘要： The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, platelet activation, leukocyte activation, and platelet-leukocyte adhesion associated with such procedures.
摘要翻译： 公开了使用抗C5抗体来减少与体外循环程序（例如体外循环手术）相关的免疫和止血系统的功能障碍。 已经发现抗体显着降低与这些程序相关的补体活化，血小板活化，白细胞活化和血小板 - 白细胞粘附。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.056 秒)